Back to Trials
NCT07219940PHASE1RecruitingAccepts Healthy Volunteers

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

Shine-On Biomedical Co., Ltd.

Start Date

12/1/2025

Completion Date

3/1/2027

Summary

The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Male or female subjects aged ≥ 18 years old 2. Overtly healthy subject, who is considered to be generally healthy based on medical history, 12-lead ECG, and physical examinations, as judged by the Investigator 3. Able to understand and comply with procedures in the protocol as judged by Investigator and sign the informed consent form (ICF) 4. Adequate organ function Exclusion Criteria: 1. With known or suspected to be hypersensitivity to HLA-G related treatment. 2. Confirmed active HIV, HBV, or HCV infection 3. With active fungal, bacterial, viral or atypical infection requiring systemic medication 4. History of cancer (malignancy) or have ever received any anti-cancer therapy 5. Has ever received cell therapy or organ transplantation 6. Substance abuse or addictive use of drugs for nonmedical purposes 7. Female subject is lactating, has a positive pregnancy test or refuse to practice highly effective contraception 8. Male subjects with a female spouse/partner who is of childbearing potential refuse to adopt at least one highly effective method of contraception

Interventions

DRUG

SOB100

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy SubjectsExosomeTargeted Therapy

Locations

Parexel International - Baltimore Early Phase Clinical Unit

Baltimore, Maryland 21225

United States